Ligand to Participate in Two Upcoming Investor Conferences
September 01 2017 - 9:00AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announces that company executives are scheduled to participate in
the following upcoming investor conferences:
- Citi’s 12th Annual Biotech Conference
in Boston. Ligand will attend the conference on Wednesday,
September 6, 2017 with one-on-one meetings only. Matt Korenberg,
CFO will attend for Ligand.
- Rodman & Renshaw 19th Annual Global
Investment Conference in New York City. Presentation takes place on
Monday, September 11, 2017 at 1:45 p.m. Eastern time (10:45 a.m.
Pacific time). John Higgins, CEO, Matt Foehr, President and COO and
Matt Korenberg, CFO will attend for Ligand.
A live webcast of the presentation will be available on Ligand’s
website at www.ligand.com. A replay of the presentation will be
archived on the website for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170901005110/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill(858)
550-7500investors@ligand.com@Ligand_LGNDorLHABruce Voss(310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2024 to May 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From May 2023 to May 2024